Chemo testicular nonseminoma may increase risk of short-term CVD death
the ONA take:
Patients with testicular nonseminoma have significantly increased cardiovascular disease mortality after chemotherapy but not surgery, a new study published online ahead of print in the Journal of Clinical Oncology has shown.
Previous research from the 1960s has shown that long-term survivors of testicular cancer who were treated with chemotherapy have increased risks of incidence cardiovascular disease, but there is a lack of data on whether treatment increases cardiovascular mortality during, shortly after, and for two decades after diagnosis in a time where most patients with testicular cancer receive cisplatin-based regimens.
For the study, researchers analyzed data from 15,006 patients with testicular nonseminoma from the Surveillance, Epidemiology, and End Results (SEER) database. Of those, 6,909 initially received chemotherapy and 8,097 initially underwent surgery without radiation.
Results showed that cardiovascular disease mortality was significantly increased after chemotherapy but not surgery. Researchers found that increased cardiovascular disease mortality was limited to the first year after testicular cancer diagnosis.
The authors conclude that the increased short-term risk of cardiovascular disease death should be investigated further in analytic studies.
Patients with testicular nonseminoma have significantly increased cardiovascular disease mortality after chemotherapy.
Sign Up for Free e-newsletters
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Study Reveals Relationship of Sleep Duration, Diabetes Risk in Cancer Survivors
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Risk for Colon Cancer, Osteogenic Sarcoma Higher With Presence of Diamond-Blackfan Anemia
- G-CSF Support Increases Overall Survival, But Risk of Secondary Malignancies Also Higher
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
- Outcomes Worse for Minimally Invasive Hysterectomy vs Open Surgery
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|